P3H4 Promotes Malignant Progression of Lung Adenocarcinoma via Interaction with EGFR

P3H4 Promotes Malignant Progression of Lung Adenocarcinoma via Interaction with EGFR

Lung cancer is associated with the greatest number of cancer-related deaths worldwide. Lung adenocarcinoma (LUAD) accounts for 85% of all cases of lung cancer. Despite recent advances in treatment, the 5-year survival rate remains less than 15%. Thus, the diagnostic and therapeutic role of LUAD rema...

Full description

Bibliographic Details
Main Authors:	Chen Fang, Yingkuan Liang, Yong Huang, Dong Jiang, Jiaxi Li, Haitao Ma, Lingchuan Guo, Wei Jiang, Yu Feng
Format:	Article
Language:	English
Published:	MDPI AG 2022-07-01
Series:	Cancers
Subjects:	lung adenocarcinoma P3H4 EGFR metabolism
Online Access:	https://www.mdpi.com/2072-6694/14/13/3243

Similar Items

Rechallenge with EGFR-TKI after failure of immunotherapy is considered an effective treatment for advanced lung adenocarcinoma patients with EGFR exon 19 deletion: a case report
by: Shubin Chen, et al.
Published: (2023-06-01)

An Explainable Radiogenomic Framework to Predict Mutational Status of KRAS and EGFR in Lung Adenocarcinoma Patients
by: Berardino Prencipe, et al.
Published: (2023-06-01)

Prognostic analysis of patients with mutant and wild-type EGFR gene lung adenocarcinoma
by: Zheng H, et al.
Published: (2019-07-01)

Low-Dose Nicotine Activates EGFR Signaling via α5-nAChR and Promotes Lung Adenocarcinoma Progression
by: Mong-Lien Wang, et al.
Published: (2020-09-01)

Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma
by: Lingzhi Hong, et al.
Published: (2022-07-01)

Heterogeneous components of lung adenocarcinomas confer distinct EGFR mutation and PD-L1 expression
by: Yiran Cai, et al.
Published: (2020-02-01)

EGFR-Mutated Breast Metastasis of Lung Adenocarcinoma: A Case Report
by: Eric Dansin, et al.
Published: (2015-03-01)

Complex Differential Diagnosis between Primary Breast Cancer and Breast Metastasis from EGFR-Mutated Lung Adenocarcinoma: Case Report and Literature Review
by: Carmine Valenza, et al.
Published: (2021-08-01)

Miliary brain metastases from lung adenocarcinoma with EGFR (L858R) and CTNNB1 mutations
by: Michihiro Kunishige, et al.
Published: (2023-12-01)

Comparing the Efficacy of Two Generations of EGFR-TKIs: An Integrated Drug–Disease Mechanistic Model Approach in EGFR-Mutated Lung Adenocarcinoma
by: Hippolyte Darré, et al.
Published: (2024-03-01)

STE029 Overcomes EGFR-TKI Resistance in Human Lung Adenocarcinoma
by: Lin HUANG, et al.
Published: (2022-11-01)

Predictive Role of EGFR Mutation Status on Postoperative Prognosis in Patients  with Resected Lung Adenocarcinomas
by: Hao BAI, et al.
Published: (2013-04-01)

Finding the Right Way to Target EGFR in Glioblastomas; Lessons from Lung Adenocarcinomas
by: Ya Gao, et al.
Published: (2018-12-01)

Retrospective study of EGFR‐mutant lung adenocarcinoma with bone metastatic clinical features
by: Liyan Gu, et al.
Published: (2023-01-01)

Comparison between Three Different Techniques for the Detection of EGFR Mutations in Liquid Biopsies of Patients with Advanced Stage Lung Adenocarcinoma
by: Milena Casula, et al.
Published: (2023-03-01)

Dual Targeting of EGFR with PLK1 Exerts Therapeutic Synergism in Taxane-Resistant Lung Adenocarcinoma by Suppressing ABC Transporters
by: Sol-Bi Shin, et al.
Published: (2021-09-01)

The HIF-1α/PKM2 Feedback Loop in Relation to EGFR Mutational Status in Lung Adenocarcinoma
by: Yuan Wang, et al.
Published: (2024-12-01)

Distribution and prognostic impact of EGFR and KRAS mutations according to histological subtype and tumor invasion status in pTis-3N0M0 lung adenocarcinoma
by: Masaoki Ito, et al.
Published: (2023-03-01)

Routine Clinically Detected Increased ROS1 Transcripts Are Related With ROS1 Expression by Immunohistochemistry and Associated With EGFR Mutations in Lung Adenocarcinoma
by: Karl Grenier, MD, PhD, et al.
Published: (2023-07-01)

Case report: EGFR fusion mutation combined with EGFR amplification responds to EGFR-TKI therapy
by: Zhulin Wang, et al.
Published: (2024-03-01)

Dual-energy CT-based radiomics in predicting EGFR mutation status non-invasively in lung adenocarcinoma
by: Jing-Wen Ma, et al.
Published: (2024-01-01)

Relationship between the image characteristics of artificial intelligence and EGFR gene mutation in lung adenocarcinoma
by: Guoping Zhou, et al.
Published: (2023-01-01)

Successful treatment of a patient with advanced lung adenocarcinoma (EGFR-T790M and C797S cis) with lazertinib: A case report and literature review
by: Yue Fang, et al.
Published: (2023-01-01)

Clinical characteristics and MRI based radiomics nomograms can predict iPFS and short-term efficacy of third-generation EGFR-TKI in EGFR-mutated lung adenocarcinoma with brain metastases
by: Haoran Qi, et al.
Published: (2024-03-01)

Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer
by: Kamal Eltayeb, et al.
Published: (2022-01-01)

Characterizing the secretome of EGFR mutant lung adenocarcinoma
by: Jennifer K. Luu, et al.
Published: (2024-01-01)

Case report: Rechallenge with EGFR–TKIs after immunotherapy in EGFR–mutated non–small cell lung cancer with leptomeningeal metastasis
by: Chunfa Qian, et al.
Published: (2022-11-01)

Lung adenocarcinoma relapse with emerging EGFR mutation following complete response of small cell lung cancer warrants routine re-biopsy: A case report
by: Minna Zhang, et al.
Published: (2022-10-01)

Persistent response of furmonertinib plus anlotinib in a lung adenocarcinoma patient with an EGFR exon 20 insertion mutation: A case report
by: Xuesong Chen, et al.
Published: (2023-02-01)

Circulating <i>EGFR</i> Mutations in Patients with Lung Adenocarcinoma by Circulating Tumor Cell Isolation Systems: A Concordance Study
by: Shih-Hong Li, et al.
Published: (2022-09-01)

MMP11 is associated with the immune response and immune microenvironment in EGFR-mutant lung adenocarcinoma
by: Lu Bai, et al.
Published: (2023-01-01)

In‐depth proteomics reveals the characteristic developmental profiles of early lung adenocarcinoma with epidermal growth factor receptor mutation
by: Tomoko Dai, et al.
Published: (2023-05-01)

Case report: Target and immunotherapy of a lung adenocarcinoma with enteric differentiation, EGFR mutation, and high microsatellite instability
by: Meiling Yang, et al.
Published: (2024-01-01)

AFATINIB IN THE TREATMENT OF METASTATIC AND LOCALLY ADVANCED LUNG ADENOCARCINOMA WITH EGFR MUTATIONS: NEW SIDES STUDIED POSSIBILITIES
by: E. V. Karabina, et al.
Published: (2017-11-01)

Almonertinib-induced interstitial lung disease in a lung adenocarcinoma patient complicated with interstitial lung abnormality
by: Qian Zhou, et al.
Published: (2023-03-01)

Erlotinib in combined therapy of common lung adenocarcinoma in the presence of EGFR gene mutation
by: S. V. Orlov, et al.
Published: (2019-06-01)

Influence of the Timing of Leptomeningeal Metastasis on the Outcome of <i>EGFR</i>-Mutant Lung Adenocarcinoma Patients and Predictors of Detectable <i>EGFR</i> Mutations in Cerebrospinal Fluid
by: Pei-Ya Liao, et al.
Published: (2022-06-01)

Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma
by: Verma, Akash, et al.
Published: (2017)

DCLK1 Drives EGFR-TKI-Acquired Resistance in Lung Adenocarcinoma by Remodeling the Epithelial–Mesenchymal Transition Status
by: Rui Yan, et al.
Published: (2023-05-01)

EGFR mutation status yield from bronchoalveolar lavage in patients with primary pulmonary adenocarcinoma compared to a venous blood sample and tissue biopsy
by: Nikolay Yanev, et al.
Published: (2021-05-01)